Published in Prostate on July 01, 2004
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 1.29
HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One (2013) 1.25
HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One (2012) 1.25
HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19
HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 1.15
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res (2009) 1.15
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma (2011) 1.07
Cellular senescence and chromatin organisation. Br J Cancer (2007) 1.06
Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig Dis Sci (2005) 0.94
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. PLoS One (2014) 0.87
Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther (2014) 0.86
AKNA: another AT-hook transcription factor "hooking-up" with inflammation. Cell Res (2011) 0.85
The high mobility group A1 molecular switch: turning on cancer - can we turn it off? Expert Opin Ther Targets (2014) 0.84
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology (2012) 0.82
HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency. Mol Cell Biol (2009) 0.82
Knockdown of MBP-1 in human foreskin fibroblasts induces p53-p21 dependent senescence. PLoS One (2008) 0.81
Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget (2017) 0.78
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia (2016) 0.76
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr Mol Med (2016) 0.75
4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation. Oncol Lett (2016) 0.75
TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion. Int J Oncol (2017) 0.75
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. Sci Rep (2017) 0.75
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
Training the urologic scientist---an endangered species. Urology (2002) 1.55
A novel method of data analysis for utilization of red blood cell transfusion. Transfusion (2013) 1.52
Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol (2009) 1.49
HMGA2 participates in transformation in human lung cancer. Mol Cancer Res (2008) 1.44
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One (2013) 1.25
HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One (2012) 1.25
HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat (2002) 1.23
HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19
Bacterial survival strategies suggest rethinking cancer cooperativity. Trends Microbiol (2012) 1.19
HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 1.15
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res (2009) 1.15
HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol (2009) 1.14
Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene (2004) 1.11
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma (2011) 1.07
High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol (2012) 1.05
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res (2004) 1.00
Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther (2008) 0.99
The cancer diaspora: Metastasis beyond the seed and soil hypothesis. Clin Cancer Res (2013) 0.98
High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res (2002) 0.98
Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. J Cell Biochem (2014) 0.96
Concentrations of B vitamins and homocysteine in children with sickle cell anemia. South Med J (2004) 0.93
Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem (2003) 0.87
Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion (2014) 0.87
Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther (2014) 0.86
Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res (2004) 0.86
AKNA: another AT-hook transcription factor "hooking-up" with inflammation. Cell Res (2011) 0.85
HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk Lymphoma (2013) 0.84
Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer (2008) 0.84
The high mobility group A1 molecular switch: turning on cancer - can we turn it off? Expert Opin Ther Targets (2014) 0.84
Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia. Pediatr Blood Cancer (2010) 0.82
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology (2012) 0.82
HMGA1 drives metabolic reprogramming of intestinal epithelium during hyperproliferation, polyposis, and colorectal carcinogenesis. J Proteome Res (2015) 0.82
The Efficacy and Utility of Acute Normovolemic Hemodilution. Anesth Analg (2015) 0.80
Characterizing metabolic changes in human colorectal cancer. Anal Bioanal Chem (2015) 0.77
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma (2013) 0.77
Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. Case Rep Hematol (2013) 0.76
IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells. Cell Cycle (2015) 0.75
Changing the energy habitat of the cancer cell in order to impact therapeutic resistance. Mol Pharm (2011) 0.75
A conversation between Darracott Vaughan and Donald S. Coffey. BJU Int (2004) 0.75
Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. Pediatr Blood Cancer (2010) 0.75